EIDD-1931 Nucleoside Analogue Inhibits Enterovirus RNA Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for enterovirus infections lack specific antiviral drugs, relying mainly on symptomatic and supportive therapies, which are inadequate for managing diverse and potentially severe symptoms caused by enteroviruses such as hand-foot-and-mouth disease, aseptic meningitis, and myocarditis.
Innovation Solution
The compound represented by Formula I, its geometric isomers, pharmaceutically acceptable salts, solvates, and hydrates, are used to inhibit enterovirus replication and are formulated into pharmaceutical compositions for treating enterovirus infections, demonstrating antiviral activity against various enteroviruses, including EV-A71, by inhibiting viral RNA replication and protein production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If symptomatic and supportive therapy is used for enterovirus infection, then treatment can be provided for diverse symptoms, but no specific antiviral effect is achieved
Solution Approach 1:
The patent uses EIDD-1931 as an intermediary substance that specifically targets enterovirus replication mechanisms. The compound acts as a nucleoside analogue that interferes with viral RNA synthesis, providing a specific antiviral mechanism while allowing continued symptomatic management of diverse clinical presentations
2Reliability
If no specific antiviral drugs are available, then treatment cost and complexity are reduced, but patient outcomes worsen due to inadequate symptom management
Solution Approach 1:
The treatment approach is segmented into two distinct components: (1) EIDD-1931 for specific antiviral action against enterovirus replication, and (2) conventional symptomatic and supportive therapy for managing clinical manifestations. This segmentation allows each component to address its specific function without unnecessary complexity
Data Source
Figure 1~2F
Figure 3A~4C
Figure 5A~6D
AI summary
The present invention relates to use of a compound represented by formula I, a geometric isomer thereof or a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof and a pharmaceutical composition comprising the compound in the preparation of a drugs for treating diseases or infections caused by enteroviruses.